Cohance Lifesciences has appointed industry veteran Umang Vohra as Executive Chairman and Group CEO to drive its next phase of global growth and transformation.
Glimpse:
Cohance Lifesciences has named former Cipla CEO Umang Vohra as Executive Chairman (from May 1, 2026) and Group CEO (from May 20, 2026). The move signals a strategic leadership shift aimed at accelerating growth and strengthening its global CDMO platform.
Cohance Lifesciences has announced a major leadership transition with the appointment of Umang Vohra as Executive Chairman and Group Chief Executive Officer, marking a pivotal moment in the company’s growth journey.
Vohra, a highly respected leader in the pharmaceutical industry and former Managing Director and Global CEO of Cipla, will assume the role of Executive Chairman from May 1, 2026, and take on the Group CEO position from May 20, 2026.
He succeeds Vivek Sharma, who is stepping down from his role for personal reasons but will continue as an advisor for the next nine months to ensure a smooth leadership transition.
The appointment reflects a deliberate strategic decision by the board to bring in a leader with proven expertise in scaling global pharmaceutical businesses. With over three decades of experience, Vohra is expected to lead Cohance through its next phase of transformation, focusing on innovation, operational excellence, and global expansion.
Cohance Lifesciences operates as a technology driven Contract Development and Manufacturing Organization (CDMO), specializing in complex chemistry, advanced APIs, antibody drug conjugates (ADCs), and oligonucleotides. The company aims to strengthen its position as a global partner for pharmaceutical innovators.
Market response to the announcement has been strongly positive, with the company’s shares surging nearly 20%, reflecting investor confidence in Vohra’s leadership and the company’s long term growth prospects.
Industry experts view this leadership change as a critical step for Cohance, especially as it navigates regulatory challenges and seeks to accelerate commercialization of its R&D pipeline while expanding its global footprint.
Overall, the appointment signals Cohance Lifesciences’ ambition to evolve into a leading global CDMO player, backed by experienced leadership and a strong scientific foundation.
“This leadership move is designed to steer Cohance into its next phase of transformation and global growth.”
By
HB Team
